Class information for:
Level 1: CANC VACCINE DEV PROGRAM//CANC IMMUNOL IMMUNOTHER Y//TUMOR VACCINE GRP

Basic class information
Class id #P Avg. number of
references		 Database coverage
of references
16780 636 47.2 92%


Bar chart of Publication_year

Last years might be incomplete

Hierarchy of classes
The table includes all classes above and classes immediately below the current class.


Cluster id Level Cluster label #P
0 4 BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY 4064930
10 3       IMMUNOLOGY//JOURNAL OF IMMUNOLOGY//IMMUNOL 134299
140 2             IMMUNOTHERAPY//DENDRITIC CELLS//CANCER IMMUNOLOGY IMMUNOTHERAPY 23462
16780 1                   CANC VACCINE DEV PROGRAM//CANC IMMUNOL IMMUNOTHER Y//TUMOR VACCINE GRP 636

Terms with highest relevance score


rank Term termType Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CANC VACCINE DEV PROGRAM address 800165 3% 83% 20
2 CANC IMMUNOL IMMUNOTHER Y address 540206 5% 35% 32
3 TUMOR VACCINE GRP address 518363 5% 35% 31
4 CANC SECT address 379036 4% 34% 23
5 HER 2 NEU authKW 347671 15% 8% 96
6 HER 2 NEU PEPTIDES authKW 341405 1% 89% 8
7 ONCOANTIGENS authKW 336072 1% 100% 7
8 JOYCE MURTHA BREAST CARE address 288062 1% 100% 6
9 TRANSLAT MED WOMENS HLTH address 219453 3% 29% 16
10 E75 authKW 197512 2% 34% 12

Web of Science journal categories


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 Oncology 8368 59% 0% 374
2 Immunology 3525 36% 0% 230
3 Medicine, Research & Experimental 1058 16% 0% 102
4 Biotechnology & Applied Microbiology 140 8% 0% 49
5 Genetics & Heredity 56 5% 0% 34
6 Cell Biology 13 5% 0% 29
7 Biochemical Research Methods 2 2% 0% 10
8 Obstetrics & Gynecology 1 1% 0% 8
9 Pathology 1 1% 0% 7
10 Mathematical & Computational Biology 0 0% 0% 3

Address terms


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CANC VACCINE DEV PROGRAM 800165 3% 83% 20
2 CANC IMMUNOL IMMUNOTHER Y 540206 5% 35% 32
3 TUMOR VACCINE GRP 518363 5% 35% 31
4 CANC SECT 379036 4% 34% 23
5 JOYCE MURTHA BREAST CARE 288062 1% 100% 6
6 TRANSLAT MED WOMENS HLTH 219453 3% 29% 16
7 RENA ROWEN BREAST 171463 1% 71% 5
8 CLIN BIOL SCI 109773 11% 3% 67
9 BIOTECHNOL SATELLITE UNIT BOLOGNA 108022 0% 75% 3
10 US MIL CANC 96987 2% 14% 14

Journals


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class
1 CANCER IMMUNOLOGY IMMUNOTHERAPY 25457 8% 1% 48
2 ONCOIMMUNOLOGY 11282 2% 2% 15
3 CANCER RESEARCH 4094 9% 0% 58
4 IMMUNOTHERAPY 3254 1% 1% 7
5 CLINICAL CANCER RESEARCH 2878 5% 0% 30
6 EXPERT REVIEW OF VACCINES 2456 1% 1% 8
7 JOURNAL OF IMMUNOTHERAPY 2297 1% 1% 9
8 BREAST CANCER RESEARCH AND TREATMENT 2124 3% 0% 18
9 INTERNATIONAL JOURNAL OF CANCER 2107 5% 0% 30
10 BREAST CANCER RESEARCH 1776 1% 0% 9

Author Key Words


Rank Term Chi square Shr. of publ. in
class containing
term		 Class's shr. of
term's tot. occurrences		 #P with
term in
class		 LCSH search Wikipedia search
1 HER 2 NEU 347671 15% 8% 96 Search HER+2+NEU Search HER+2+NEU
2 HER 2 NEU PEPTIDES 341405 1% 89% 8 Search HER+2+NEU+PEPTIDES Search HER+2+NEU+PEPTIDES
3 ONCOANTIGENS 336072 1% 100% 7 Search ONCOANTIGENS Search ONCOANTIGENS
4 E75 197512 2% 34% 12 Search E75 Search E75
5 NELIPEPIMUT S 192041 1% 100% 4 Search NELIPEPIMUT+S Search NELIPEPIMUT+S
6 IMMUNOPREVENTION 161710 1% 42% 8 Search IMMUNOPREVENTION Search IMMUNOPREVENTION
7 CANCER IMMUNOPREVENTION 153631 1% 80% 4 Search CANCER+IMMUNOPREVENTION Search CANCER+IMMUNOPREVENTION
8 AE37 108022 0% 75% 3 Search AE37 Search AE37
9 CANCER VACCINE 104400 8% 4% 51 Search CANCER+VACCINE Search CANCER+VACCINE
10 AE37 VACCINE 96021 0% 100% 2 Search AE37+VACCINE Search AE37+VACCINE

Core articles
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c:
(1) Number of references referring to publications in the class.
(2) Share of total number of active references referring to publications in the class.
(3) Age of the article. New articles get higher score than old articles.
(4) Citation rate, normalized to year.


Rank Reference # ref.
in cl.		 Shr. of ref. in
cl.		 Citations
1 LADJEMI, MZ , JACOT, W , CHARDES, T , PELEGRIN, A , NAVARRO-TEULON, I , (2010) ANTI-HER2 VACCINES: NEW PROSPECTS FOR BREAST CANCER THERAPY.CANCER IMMUNOLOGY IMMUNOTHERAPY. VOL. 59. ISSUE 9. P. 1295 -1312 62 53% 50
2 BAXEVANIS, CN , VOUTSAS, IF , GRITZAPIS, AD , PEREZ, SA , PAPAMICHAIL, M , (2010) HER-2/NEU AS A TARGET FOR CANCER VACCINES.IMMUNOTHERAPY. VOL. 2. ISSUE 2. P. 213 -226 61 55% 23
3 LADJEMI, MZ , JACOT, W , PELEGRIN, A , NAVARRO-TEULON, I , (2011) ANTI-HER2 VACCINES: THE HER2 IMMUNOTARGETING FUTURE?.PATHOLOGIE BIOLOGIE. VOL. 59. ISSUE 3. P. 173-182 47 69% 1
4 MILANI, A , SANGIOLO, D , MONTEMURRO, F , AGLIETTA, M , VALABREGA, G , (2013) ACTIVE IMMUNOTHERAPY IN HER2 OVEREXPRESSING BREAST CANCER: CURRENT STATUS AND FUTURE PERSPECTIVES.ANNALS OF ONCOLOGY. VOL. 24. ISSUE 7. P. 1740-1748 35 63% 32
5 LOLLINI, PL , NICOLETTI, G , LANDUZZI, L , CAVALLO, F , FORNI, G , DE GIOVANNI, C , NANNI, P , (2011) VACCINES AND OTHER IMMUNOLOGICAL APPROACHES FOR CANCER IMMUNOPREVENTION.CURRENT DRUG TARGETS. VOL. 12. ISSUE 13. P. 1957-1973 55 43% 6
6 CLIFTON, GT , PEOPLES, GE , MITTENDORF, EA , (2016) THE DEVELOPMENT AND USE OF THE E75 (HER2 369-377) PEPTIDE VACCINE.FUTURE ONCOLOGY. VOL. 12. ISSUE 11. P. 1321 -1329 25 81% 0
7 TRAN, T , DINIZ, MO , DRANSART, E , GEY, A , MERILLON, N , LONE, YC , GODEFROY, S , SIBLEY, C , FERREIRA, LCS , MEDIONI, J , ET AL (2016) A THERAPEUTIC HER2/NEU VACCINE TARGETING DENDRITIC CELLS PREFERENTIALLY INHIBITS THE GROWTH OF LOW HER2/NEU-EXPRESSING TUMOR IN HLA-A2 TRANSGENIC MICE.CLINICAL CANCER RESEARCH. VOL. 22. ISSUE 16. P. 4133 -4144 30 58% 1
8 MITTENDORF, EA , PEOPLES, GE , (2016) INJECTING HOPE-A REVIEW OF BREAST CANCER VACCINES.ONCOLOGY-NEW YORK. VOL. 30. ISSUE 5. P. 475 -+ 26 54% 2
9 LOLLINI, PL , CAVALLO, F , NANNI, P , FORNI, G , (2006) VACCINES FOR TUMOUR PREVENTION.NATURE REVIEWS CANCER. VOL. 6. ISSUE 3. P. 204-216 38 38% 141
10 CLIFTON, GT , GALL, V , PEOPLES, GE , MITTENDORF, EA , (2016) CLINICAL DEVELOPMENT OF THE E75 VACCINE IN BREAST CANCER.BREAST CARE. VOL. 11. ISSUE 2. P. 116 -121 26 50% 1

Classes with closest relation at Level 1


Rank Class id link
1 13629 TUMOR IMMUNOL BIOL//SIPULEUCEL T//5T4
2 26564 RAS DERIVED PEPTIDES//P53 PEPTIDES//RAS PEPTIDES
3 1375 CANCER TESTIS ANTIGEN//NY ESO 1//MAGE
4 35026 M1B PROSTATE CANCER//BIOMARKER EPIDERMAL GROWTH FACTOR RECEPTOR EGFR//C ERB B 2 NEU GENE
5 5180 C ERBB 2//HER 2 NEU//P185
6 24733 TUMOR IMMUN TOLERANCE SECT//SV40 T ANTIGEN TRANSGENIC MICE//CCDC134
7 25112 GV1001//PA MSHA VACCINE//HTERTC27
8 24888 CANC VACCINE DEV//INNOVAT CANC THER Y//PERSONALIZED PEPTIDE VACCINE
9 2563 TRASTUZUMAB//LAPATINIB//PERTUZUMAB
10 4080 REGULATORY T CELLS//FOXP3//TUMOR INFILTRATING LYMPHOCYTES

Go to start page